 |
|
|
|
 |
|
|
| Article 1 to 10 out of 49 concerning Genentech, Inc.
|
-
Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer
(02 Mar 2010)
First Phase III Study of an Anti-Angiogenic Therapy in Advanced Ovarian Cancer to Meet Primary Endpoint
Genentech, Inc. announced that a Phase III study showed the combination of Avastin® (bevacizumab) and chemotherapy followed by maintenance use of Avastin alone increased the time women with previously untreated advanced ovarian cancer lived without ...
-
Graffinity Enters into Drug Discovery Research Collaboration with Genentech
(16 Oct 2009)
Graffinity Pharmaceuticals GmbH announced that it has entered into a drug discovery research collaboration with Genentech, Inc, a wholly-owned member of the Roche Group. With this collaboration Genentech will gain access to Graffinity’s proprietary, ...
-
Roche and Lonza Announce Opt-in for Singapore Manufacturing Facility
(31 Aug 2009)
Roche and Lonza announced that Genentech Singapore Pte. Ltd., a wholly-owned member of the Roche Group, elected to exercise an option to purchase from Lonza its cell culture biologic manufacturing facility in Singapore. The facility, which is ...
-
Dako enters collaboration with Genentech on diagnostic tests for patients with stomach cancer
(13 Aug 2009)
Dako has signed an agreement with Genentech, Inc. to collaborate on the regulatory submissions of Dako's HercepTest(TM) and HER2 FISH pharmDx(TM) as companion diagnostics for Herceptin® (trastuzumab) in patients with advanced HER2-positive stomach ...
-
Avastin plus commonly used chemotherapies improved progression-free survival in advanced breast cancer
(19 May 2009)
Data from RIBBON 1 study provides efficacy and safety information with different types of chemotherapy
Roche and Genentech provided an overview of results from the Phase III study (RIBBON 1) that showed Avastin® (bevacizumab) plus commonly used chemotherapies, including Xeloda® (capecitabine) and anthracycline-based therapies, increased the time ...
-
Roche and Genentech reach a friendly agreement to combine the two organizations and create a leader in healthcare innovation
(13 Mar 2009)
Roche intends to acquire all outstanding shares of Genentech for US$95.00 per share in cash
Roche and Genentech announced that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US$95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity ...
-
Roche intends to commence tender offer to acquire all shares of Genentech for US$ 86.50 per share in cash
(03 Feb 2009)
Roche announced that it intends to commence a cash tender offer for all outstanding publicly-held shares of Genentech at US$ 86.50 per share. Roche, which currently owns 55.8% of the Genentech outstanding shares, expects to commence the tender offer ...
-
Dako enters new collaboration with Genentech on a companion diagnostic for a targeted cancer therapy
(28 Nov 2008)
Dako has signed an agreement with Genentech, Inc. for a drug-companion diagnostic co-development program for a targeted cancer therapy. The collaboration involves the use of Dako's extensive experience in developing cancer diagnostic tests to ...
-
Genentech Announces Phase III Study of Avastin Plus Chemotherapy in Adjuvant Colon Cancer Will Continue
(23 Oct 2008)
Genentech, Inc. announced that it has been informed by the National Surgical Adjuvant Breast and Bowel Project (NSABP) that an ongoing Phase III study (NSABP C-08) of Avastin® (bevacizumab) plus chemotherapy in patients with early-stage colon cancer ...
-
Phase III Study Showed Rituxan in Combination with Chemotherapy Improved Progression-Free Survival in Patients with Relapsed CLL
(08 Oct 2008)
Study is Second Positive Phase III Trial of Rituxan Plus Chemotherapy in Most Common Adult Leukemia
Genentech, Inc. and Biogen Idec announced that a global Phase III study of Rituxan® (rituximab) in combination with fludarabine and cyclophosphamide chemotherapy met its primary endpoint of improving progression-free survival (PFS), as assessed by ...
|
|
|
|
|
Top